刘宁宁，女，籍贯山东，中共党员，广州医科大学附属第二医院心血管疾病研究所硕士研究生导师。毕业于广州医科大学，获内科学医学博士学位，师从刘金保教授。现任广东省病理生理学会心血管专业委员会委员。在Cell Research、Cell Reports、Oncogene、Cell Death and Disease、Cellular Physiology and Biochemistry, Scientific Reports、Oncotarget、Toxicology Letters、Toxicology in Vitro、BBRC等杂志发表SCI论文31篇（影响因子共计154.781），其中包括16篇第一作者及通讯作者SCI论文（影响因子共计81.663）。
研究方向：泛素-蛋白酶体系统与心血管疾病。招生专业：内科学（学术学位）联系方式：liunn425@163.com
获得奖励： 2018年 广东省****医学人才（第一批） 2017年 广州医科大学“南山****”人才计划 2017年 广州医科大学“学术骨干”培育计划 2017年 中华医学会科技奖三等奖 2016年 广州市科学技术进步奖一等奖 2015年 广州市“珠江科技新星”
在研基金项目： 1.国家自然科学基金青年项目，去泛素化酶USP14调控心肌肥大的分子机制研究，23万，主持。 2.广东省科技厅自然科学基金面上项目，去泛素化酶USP14调控动脉粥样硬化的分子机制研究，10万，主持。 3.广东省科技厅科技计划项目，金属离子去泛素化酶抑制剂在心肌肥大治疗中的作用，10万，主持。 4.广东省教育厅特色创新项目，19S蛋白酶体特异性去泛素化酶抑制对动脉粥样硬化的防治作用，5万，主持。 5.广州市科创委珠江科技新星，去泛素化酶USP14调控心肌肥大的分子机制研究，30万，主持。 6.广州市教育局市属高校科技计划项目，去泛素化酶USP14调控动脉粥样硬化的分子机制研究，8万，主持。
代表性期刊论文如下： 1.Hu M(#), Zhang Z(#), Liu B(#), Zhang S, Chai R, Chen X, Kong T, Zhang F, Zhang J, Liu S(*), Liu N(*). Deubiquitinase inhibitor auranofin attenuated cardiac hypertrophy by blocking NF-κB activation, Cellular Physiology and Biochemistry. 2018;45(6): 2421-2430. 2.Hu M, Guo G, Huang Q, Cheng C, Xu R, Li A, Liu N(*), Liu S(*). The Harsh Microenvironment in Infarcted Heart Accelerates Transplanted Bone Marrow Mesenchymal Stem Cells Injury: The Role of Injured Cardiomyocytes-derived Exosomes, Cell Death & Disease, 2018; 9:357. 3.Liao Y(#), Xia X(#), Liu N(#), Cai J, Guo Z, Li Y, Jiang L, Dou Q, Tang D, Huang H(*), Liu J(*). Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene. 2018; Epub ahead of print. 4.Liu N (#), Kong T (#), Chen X (#), Hu H, Gu H, Liu S, Chen X, Yang Q, Li A, Xiong X(*), Zhang Z(*). Ubiquitin-specific protease 14 regulates LPS-induced inflammation by increasing ERK1/2 phosphorylation and NF-kappaB activation. Molecular & Cellular Biochemistry. 2017;431:87-96. 5.Huang H(#), Guo M(#), Liu N(#), Zhao C(#), Chen H, Wang X, Liao S, Zhou P, Liao Y, Chen X, Lan X, Chen J, Xu D, Li X, Shi X, Yu L, Nie Y, Wang X, Zhang C(*), Liu J(*). Bilirubin neurotoxicity is associated with proteasome inhibition. Cell Death & Disease. 2017;8(6):e2877. 6.Liu N (#), Chai R (#), Liu B (#), Zhang Z, Zhang S, Zhang J, Liao Y, Cai J, Xia X, Li A, Liu J, Huang H(*), Liu S(*). Ubiquitin-specific protease 14 regulates cardiac hypertrophy progression by increasing GSK-3β phosphorylation. Biochemical and Biophysical Research Communications. 2016;478:1236-41. 7.Liu B (#), Liu N (#), Liu W (#), Zhang S, Zhang J, Li A, Liu S(*). Inhibition of lectin-like oxidized low-density lipoprotein receptor-1 reduces cardiac fibroblast proliferation by suppressing GATA Binding Protein 4. Biochemical and Biophysical Research Communications. 2016;475:329-34. 8.Liu N, Huang H, Dou QP, Liu J(*). Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds. Oncoscience. 2015;2:457-66. 9.Huang H(#), Hua X(#), Liu N(#), Li X, Liu S, Chen X, Zhao C, Lan X, Yang C, Dou QP, Liu J(*). Anacardic acid induces cell apoptosis associated with induction of ATF4-dependent endoplasmic reticulum stress. Toxicology Letters. 2014;228:170-8. 10.Liu N(#), Li X(#), Huang H(#), Zhao C(#), Liao S(#), Yang C(#), Liu S(#), Song W, Lu X, Lan X, Chen X, Yi S, Xu L, Jiang L, Zhao C, Dong X, Zhou P, Li S, Wang S, Shi X, Dou PQ, Wang X, Liu J(*). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014;5:5453-71. 11.Liu N(#), Liu C(#), Li X(#), Liao S(#), Song W(#), Yang C(#), Zhao C(#), Huang H(#), Guan L, Zhang P, Liu S, Hua X, Chen X, Zhou P, Lan X, Yi S, Wang S, Wang X, Dou QP, Liu J(*). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports. 2014;4:5240. 12.Liu N(#), Huang H(#), Liu S, Li X, Yang C, Dou Q, Liu J(*). Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation. Toxicology in Vitro. 2014;28:419-25. 13.Liu N(#), Huang H(#), Xu L, Hua X, Li X, Liu S, Yang C, Zhao C, Zhao C, Li S, Dou QP, Liu J(*). The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo. Toxicology Letters. 2014;224:333-40. 14.Li X(#), Liu S(#), Huang H(#), Liu N(#), Zhao C(#), Liao S(#), Yang C, Liu Y, Zhao C, Li S, Lu X, Liu C, Guan L, Zhao K, Shi X, Song W, Zhou P, Dong X, Guo H, Wen G, Zhang C, Jiang L, Ma N, Li B, Wang S, Tan H, Wang X, Dou QP(*), Liu J(*). Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Reports. 2013;3:211-22. 15.Huang H(#), Liu N(#), Guo H(#), Liao S, Li X, Yang C, Liu S, Song W, Liu C, Guan L, Li B, Xu L, Zhang C, Wang X, Dou QP, Liu J(*). L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PloS One. 2012;7:e49062. 16.Huang H(#), Liu N(#), Yang C(#), Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP(*), Liu J(*). HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PloS One. 2012;7:e52576. 17.Huang H(#), Liu N(#), Zhao K(#), Zhu C, Lu X, Li S, Lian W, Zhou P, Dong X, Zhao C, Guo H, Zhang C, Yang C, Wen G, Lu L, Li X, Guan L, Liu C, Wang X, Dou QP, Liu J(*). Sanggenon C decreases tumor cell viability associated with proteasome inhibition. Frontiers in Bioscience. 2011;3:1315-25.6. 18.Huang H(#), Zhang X(#), Li S(#), Liu N(#), Lian W(#), McDowell E, Zhou P, Zhao C, Guo H, Zhang C, Yang C, Wen G, Dong X, Lu L, Ma N, Dong W, Dou QP, Wang X(*), Liu J(*). Physiological levels of ATP negatively regulate proteasome function. Cell Research. 2010;20:1372-85.